Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its stock surge 5.98% in after-hours trading on Thursday following the release of its first-quarter 2025 financial results, which significantly outperformed analysts' expectations.
The biotechnology company reported a quarterly loss of $0.20 per share, beating the analyst consensus estimate of $0.31 by 35.48%. This marks a substantial improvement from the $0.33 per share loss reported in the same quarter last year. Revenue for the quarter came in at $52.44 million, surpassing the analyst estimate of $42.7 million by 22.77% and representing a 25.14% increase from the $41.87 million reported in the prior-year period.
Adaptive Biotechnologies' financial performance showed notable improvements across several metrics. The company's net loss for Q1 was $29.83 million, considerably better than the expected $45 million loss. Operating loss also beat estimates, coming in at $29.604 million compared to the anticipated $43.7 million. These results, coupled with the company's forward-looking guidance, including expected full-year revenue for its MRD (Minimal Residual Disease) business between $180 million and $190 million, appear to have boosted investor confidence in Adaptive Biotechnologies' growth trajectory and financial health.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.